Newsroom

Press Releases

See All

05/05/2022

Sarepta Therapeutics Launches Inaugural LGMD Grant Award Program
05/05/2022

Sarepta Therapeutics lanza el programa inaugural de concesión de subvenciones para la LGMD
05/04/2022

Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

News Features

03/15/2022

Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
11/09/2021

Patient registries: A catalyst for developing new therapies for rare diseases
08/26/2021

Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview
01/13/2021

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
12/18/2020

Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
10/14/2020

Welcome to GT‐FAQ!

Media Library

View All Media Library

Sarepta Corporate Logo

Sarepta Building Exterior thumbnail

Sarepta Building Exterior

LGMD Fact sheet thumbnail

LGMD Fact Sheet

NSAA Fact Sheet Thumbnail

NSAA Fact Sheet

Press Contact

Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052